Literature DB >> 9533448

A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation.

R Horie1, S Aizawa, M Nagai, K Ito, M Higashihara, T Ishida, J Inoue, T Watanabe.   

Abstract

About 100 amino acid residues in the C-terminal region are conserved among human, rat and murine CD30, a member of the tumor necrosis factor receptor (TNFR) superfamily, and can be separated into three subdomains with relatively higher conservation (D1, D2 and D3). Activation of NFkappaB by CD30 was shown to be mediated through interaction of TNFR-associated factor (TRAF) 1, 2 and 5 with the D2 and D3 subdomains. However, the function of the other conserved subdomain, D1, remained to be determined. Deletion of the D2 and D3 subdomains abolished interactions with TRAF2 and 5 but it did not affect NFkappaB activation. Reporter gene assays using deletion and mutant constructs of CD30 revealed that the D1 subdomain is sufficient for NFkappaB activation, without interaction with TRAF2 or 5, and that each subdomain alone can activate NFkappaB. Electrophoretic mobility shift assays revealed constitutive and CD30-induced NFkappaB activation in stable transformants of 293 cells expressing CD30 or a deletion mutant lacking D2 and D3 subdomains. Deletion of C-terminal 19 amino acid residues of the D1 subdomain abolished activation of NFkappaB. Substitution of alanine for one of the two threonine residues (amino acid position 524 and 529), one of which is a potential phosphorylation site in the D1 subdomain, also abolished the NFkappaB activation. Overexpression of the TRAF domain of TRAF2 or 5 had a dominant negative effect on the NFkappaB activation mediated by the D1 subdomain, thereby suggesting involvement of TRAF proteins in the signaling. Thus, the C-terminal 100 amino acid region of CD30 is composed of three independent functional subdomains, two of which contain binding sites for TRAF proteins. A novel domain in the cytoplasmic tail mediates NFkappaB activation, without direct interaction of TRAF2 or 5. Our observations suggest involvement of an unknown TRAF protein(s) in the signal transduction pathway of CD30.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533448     DOI: 10.1093/intimm/10.2.203

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  11 in total

1.  Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells.

Authors:  Ryouichi Horie; Takuro Watanabe; Kinji Ito; Yasuyuki Morisita; Mariko Watanabe; Takaomi Ishida; Masaaki Higashihara; Marshall Kadin; Toshiki Watanabe
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

2.  Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.

Authors:  R Horie; V Gattei; K Ito; S Imajo-Ohmi; T Tange; J Miyauchi; A Pinto; M Degan; A De Iuliis; F Tassan Mazzocco; F M Rossi; M Higashihara; T Watanabe
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.

Authors:  Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

5.  AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells.

Authors:  Mariko Watanabe; Yuji Ogawa; Kinji Ito; Masaaki Higashihara; Marshall E Kadin; Lawrence J Abraham; Toshiki Watanabe; Ryouichi Horie
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 6.  Hodgkin's lymphoma and CD30 signal transduction.

Authors:  Ryouichi Horie; Masaaki Higashihara; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

7.  Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling.

Authors:  Sarah L Buchan; Aymen Al-Shamkhani
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

8.  A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.

Authors:  Hongbo Wang; Wei Wei; Jing-Ping Zhang; Zhihui Song; Yangyang Li; Wenming Xiao; Yijun Liu; Mu-Sheng Zeng; Michael N Petrus; Craig J Thomas; Marshall E Kadin; Masao Nakagawa; Thomas A Waldmann; Yibin Yang
Journal:  Leukemia       Date:  2020-11-12       Impact factor: 12.883

9.  TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.

Authors:  Nilay Y Thakar; Dmitry A Ovchinnikov; Marcus L Hastie; Bostjan Kobe; Jeffrey J Gorman; Ernst J Wolvetang
Journal:  Mol Biol Cell       Date:  2015-01-07       Impact factor: 4.138

10.  The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB.

Authors:  Monika Schneider; Albert G Zimmermann; Reid A Roberts; Lu Zhang; Karen V Swanson; Haitao Wen; Beckley K Davis; Irving C Allen; Eda K Holl; Zhengmao Ye; Adeeb H Rahman; Brian J Conti; Timothy K Eitas; Beverly H Koller; Jenny P-Y Ting
Journal:  Nat Immunol       Date:  2012-08-05       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.